IFLR1000

Meda Skr2 billion rights issue

1/1/2015
Share offer
Select tab

SKr 2 billion

$ 225 million

Completed

1/1/2015

Overview:

  • Meda has undertaken a rights issue valued at SKr2 billion.
  • Meda is a leading international specialty pharmaceutical company listed on Nasdaq Stockholm.
  • The purpose of the rights issue is to finance part of the acquisition of Rottapharm.

Wai Yee Tsang - Journalist

Jurisdiction:

Sweden

Deal type:

Share offer

Practice area:

Capital markets : Equity

Industry sector:

Pharmaceuticals and life sciences

Firms:
Latham & Watkins

Party: Meda (Issuer)

Lindahl

Party: Meda (Issuer)

Related deals